Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Radioisotopes”

201 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 201 results

Large-scale testing (Phase 3)WithdrawnNCT01860742
What this trial is testing

Randomized Phase III of PRRT Versus Interferon

Who this might be right for
Gastro-intestinal Neuroendocrine Tumors
Jules Bordet Institute
Very early researchStudy completedNCT02323217
What this trial is testing

I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers

Who this might be right for
Healthy VolunteersAlzheimer DiseaseMolecular Imaging
Imperial College London 20
Not applicableNot Yet RecruitingNCT07538791
What this trial is testing

Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)

Who this might be right for
PheochromocytomasParagangliomas
Azienda USL Reggio Emilia - IRCCS 210
Early research (Phase 1)Looking for participantsNCT05870423
What this trial is testing

Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors

Who this might be right for
Neuroendocrine TumorsPeptide Receptor Radionuclide Therapy
Erasmus Medical Center 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT02754297
What this trial is testing

Personalized PRRT of Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsCarcinoid TumorCarcinoma, Neuroendocrine
CHU de Quebec-Universite Laval 275
Not applicableUnknownNCT05072561
What this trial is testing

Feasibility of Radioisotope-guided Excision of Mediastinal Lymph Nodes in Patients With Non-small Cells Lung Carcinoma

Who this might be right for
Lung Cancer
Istituto Clinico Humanitas 60
Testing effectiveness (Phase 2)Ended earlyNCT04023331
What this trial is testing

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Who this might be right for
NeuroblastomaRelapsed NeuroblastomaRefractory Neuroblastoma
Clarity Pharmaceuticals Ltd 21
Early research (Phase 1)WithdrawnNCT06411301
What this trial is testing

A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors

Who this might be right for
Multiple Myeloma, RefractoryMultiple Myeloma in RelapseMultiple Myeloma Progression
Jules Bordet Institute
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06880757
What this trial is testing

177Lu-FAP-2286 Treatment in Urethelial Neoplasms: Utility and Safety as a Novel Treatment.

Who this might be right for
Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
Ankara University 10
Early research (Phase 1)UnknownNCT06081322
What this trial is testing

Evaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors

Who this might be right for
Advanced Pancreatic Cancer and Cholangiocarcinoma
Zhejiang University 29
Not applicableStudy completedNCT05427032
What this trial is testing

HRQoL During PRRT in Patients With NETs

Who this might be right for
Neuroendocrine TumorsQuality of LifePeptide Receptor Radionuclide Therapy
Uppsala University 756
Not applicableStudy completedNCT00282711
What this trial is testing

The WOMEN Study: What is the Optimal Method for Ischemia Evaluation in WomeN?

Who this might be right for
Coronary Artery DiseaseHeart DiseaseCoronary Arteriosclerosis+2 more
Hartford Hospital 824
Testing effectiveness (Phase 2)Study completedNCT02230176
What this trial is testing

Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II

Who this might be right for
Pancreatic Neuroendocrine Carcinoma
Gustave Roussy, Cancer Campus, Grand Paris 84
Testing effectiveness (Phase 2)Study completedNCT04385992
What this trial is testing

Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET

Who this might be right for
Neuroendocrine Tumors
IRCCS San Raffaele 31
Not applicableUnknownNCT04331912
What this trial is testing

PFS and OS of Patients With Advanced Neuroendocrine Cancer (NEN) After Systemic Treatment

Who this might be right for
Neuroendocrine Tumors
University of Warmia and Mazury 100
Not applicableEnded earlyNCT02043535
What this trial is testing

CO2 as a Stress Agent for Perfusion Imaging

Who this might be right for
Coronary Artery Disease
Ottawa Heart Institute Research Corporation 20
Very early researchEnded earlyNCT02874820
What this trial is testing

I2PETPG - Imidazoline2 Binding Sites in a Group of Participants Diagnosed With AD

Who this might be right for
Alzheimer Disease
Imperial College London 2
Testing effectiveness (Phase 2)Study completedNCT03490032
What this trial is testing

68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)

Who this might be right for
Prostate Cancer Metastatic
Advanced Accelerator Applications 30
Testing effectiveness (Phase 2)Study completedNCT03732781
What this trial is testing

Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC

Who this might be right for
Peritoneal CarcinomaColorectal Carcinoma
Oncoinvent Solutions AS 47
Not applicableAvailableNCT06980506
What this trial is testing

MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

Who this might be right for
CancerSolid TumorSolid Tumor, Adult
Monopar Therapeutics
Load More Results